Amycretin, now named zenagamtide, is an experimental Novo Nordisk peptide that activates the receptors for GLP-1 and amylin, two hormones involved in appetite and blood sugar.1,4 It is not FDA-approved. The sources reviewed here describe it only in clinical trials, and none reports an approval in any country.1,4,5,6,7,8,9,10 Published randomized trials report weight loss in early studies and lower blood sugar in a Phase 2 diabetes trial, with common gastrointestinal side effects. Each trial had fewer than 300 participants.2,3,4 Novo Nordisk has registered Phase 3 trials of zenagamtide in obesity, type 2 diabetes and cardiovascular disease on ClinicalTrials.gov. None had posted results when PeptideScanner retained the six records cited here.5,6,7,8,9,10
Amycretin at a glance
What it is
An investigational single-molecule agonist of the GLP-1 and amylin receptors from Novo Nordisk. The 2026 Phase 2 report names it zenagamtide (formerly amycretin) and says it also acts on calcitonin receptors.1,4
FDA status
Not FDA-approved. The sources reviewed here describe it only in clinical trials sponsored by Novo Nordisk, including registered Phase 3 trials.1,4,5,6,7,8,9,10
Human evidence
Smaller randomized, placebo-controlled trials: two early trials in adults with overweight or obesity and a Phase 2 trial in type 2 diabetes. Registered Phase 3 trials have not reported results.2,3,4,5,6,7,8,9,10
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is amycretin?
Amycretin is an experimental drug being developed by Novo Nordisk, which ClinicalTrials.gov lists as the sponsor of the trial records cited on this profile.1,5,6,7,8,9,10
A 2026 Lancet report describes zenagamtide, formerly amycretin, as a single molecule that activates the receptors for GLP-1, amylin and calcitonin. Novo Nordisk’s Phase 3 trials are registered under the name zenagamtide.4,5,6,7,8,9,10
How is amycretin thought to work?
The published trial reports describe amycretin as a unimolecular GLP-1 and amylin receptor agonist, meaning one molecule designed to mimic two hormones that help regulate appetite and blood sugar.2,3
The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.2,4
What do human studies show?
A first-in-human randomized, placebo-controlled trial in 144 adults with overweight or obesity was designed mainly to assess safety. Adverse events were mild or moderate, and gastrointestinal events were common.2
In a randomized Phase 1b/2a trial in 125 adults with overweight or obesity lasting up to 36 weeks, estimated weight reductions were greater with amycretin than placebo; gastrointestinal events were common and many participants withdrew.3
In a 36-week randomized, placebo-controlled Phase 2 trial in 262 adults with type 2 diabetes, HbA1c, a measure of long-term blood sugar, improved more with the drug than with placebo. Gastrointestinal adverse events were common.4
These were short trials with mostly safety or blood-sugar outcomes, and they do not show long-term benefits or rare harms.2,3,4
The Phase 3 trials registered under the name zenagamtide had not reported results when PeptideScanner retained their ClinicalTrials.gov records: two were recruiting and four were not yet recruiting.5,6,7,8,9,10
What the evidence base contains
Controlled human trial A first-in-human, double-blind, randomized, placebo-controlled Phase 1 trial in 144 adults with overweight or obesity, designed mainly to assess safety.2
Controlled human trial A randomized, placebo-controlled Phase 1b/2a trial in 125 adults with overweight or obesity at one research center, lasting up to 36 weeks.3
Controlled human trial A 36-week double-blind, randomized, placebo-controlled Phase 2 trial in which 262 adults with type 2 diabetes were randomized, published in The Lancet in 2026.4
Registered trial without results Six randomized Phase 3 trials of zenagamtide sponsored by Novo Nordisk and registered on ClinicalTrials.gov, none with posted results.5,6,7,8,9,10
No. Amycretin remains in clinical trials. None of the sources reviewed here reports an approval of amycretin or zenagamtide in any country.1,4,5,6,7,8,9,10
A Novo Nordisk trial in Japanese men with obesity is listed on ClinicalTrials.gov as completed, in a record last updated on March 5, 2025.1
The 2026 Phase 2 report was published under the name zenagamtide and describes it as formerly amycretin.4
ClinicalTrials.gov lists Novo Nordisk Phase 3 trials of zenagamtide in weight management. AMAZE 9 and AMAZE 13 compare it with placebo for weight loss in adults with obesity or overweight, the second in Asia, and AMBIENCE compares it with placebo in about 8,500 people with cardiovascular disease and overweight or obesity, with major cardiovascular events as its main outcome.5,6,8
Three further Phase 3 trials in type 2 diabetes measure HbA1c: AMBITION 1 and AMBITION 2 compare zenagamtide with placebo, the second in people who also have chronic kidney disease, and AMBITION 7 compares it with insulin glargine in people at increased cardiovascular risk. The registry records were last updated between September 1 and November 12, 2026.7,9,10
Registering a trial does not show that a drug works or is safe.5,6,7,8,9,10
Timeline
Results of the first two randomized amycretin trials are published in The Lancet.2,3
ClinicalTrials.gov updates the record of a completed Novo Nordisk amycretin trial in Japanese men.1
Results of a Phase 2 trial in type 2 diabetes are published under the name zenagamtide.4
ClinicalTrials.gov first posts AMAZE 13, the earliest-registered of the Phase 3 zenagamtide trials cited here.5
ClinicalTrials.gov first posts AMBITION 1 and AMBITION 2, Phase 3 zenagamtide trials in type 2 diabetes.9,10
What is still unknown?
Whether its effects on weight and blood sugar hold up in larger, longer trials: the published trials lasted up to 36 weeks and had fewer than 300 participants each.2,3,4
Its long-term safety and effects on outcomes such as heart disease, which the published trials did not measure.2,3,4
What the Phase 3 trials will find: ClinicalTrials.gov lists their estimated primary completion dates between 2028 and 2030.5,6,7,8,9,10
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Amycretin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Amycretin are the records PeptideScanner has selected and published, not every registration or paper about Amycretin. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
In clinical trials; not FDA-approved. Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.↗↗↗↗↗↗↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.↗↗↗↗↗
What the reviewed sources report
Early trials reported weight reductions but were designed primarily to assess safety and tolerability. Later zenagamtide studies reported improved glycated hemoglobin in type 2 diabetes. Gastrointestinal adverse events and study discontinuations matter when interpreting these findings.↗↗↗↗
What remains unresolved?
How durable are effects after treatment ends, and what do longer studies show about serious harms?↗↗↗↗
How do results differ by formulation, population, attrition and the analysis of missing outcomes?↗↗↗↗
Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.12345
Bottom line from this bounded source set
Early trials reported weight reductions but were designed primarily to assess safety and tolerability. Later zenagamtide studies reported improved glycated hemoglobin in type 2 diabetes. Gastrointestinal adverse events and study discontinuations matter when interpreting these findings.1234
Reviewed study record
Oral amycretin: first-in-human study
Design
A blinded randomized placebo-controlled phase 1 study contained several escalating-exposure parts.1
Population
The study enrolled 144 adults with overweight or obesity across its parts.1
Outcomes reported
Treatment-emergent adverse events were reported in 89 participants and were mild or moderate; gastrointestinal events were common.1
Limitations
Safety was the primary endpoint; weight-related measures were exploratory. Small cohorts and short follow-up do not establish long-term clinical benefit or safety.1
Reviewed study record
Subcutaneous amycretin: phase 1b/2a study
Design
A randomized placebo-controlled multipart study assessed safety and secondary body-weight changes over up to 36 weeks.2
Population
The study randomized 125 adults with overweight or obesity at one research center.2
Outcomes reported
Estimated weight reductions were greater with amycretin. Gastrointestinal events were common, and the authors reported many study withdrawals.2
Limitations
Primary endpoints concerned adverse events. Small cohorts, different observation lengths and substantial attrition limit comparisons and interpretation of weight estimates.2
Reviewed study record
Oral zenagamtide: phase 2 diabetes cohort
Design
A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.3
Population
This report included 186 adults with type 2 diabetes receiving metformin with or without an SGLT2 inhibitor.3
Outcomes reported
All three active groups improved glycated hemoglobin compared with placebo. Gastrointestinal events were common; seven participants in active groups had serious adverse events.3
Limitations
The primary analysis used on-treatment data without rescue medication. Glycemic improvement does not establish reduction in long-term complications; this cohort shares a protocol with the subcutaneous report.3
Reviewed study record
Subcutaneous zenagamtide: phase 2 diabetes cohort
Design
A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.4
Population
This route cohort randomized 262 adults with type 2 diabetes; 261 received treatment.4
Outcomes reported
Active groups improved glycated hemoglobin compared with placebo. Gastrointestinal adverse events were common; serious adverse events were reported in active and placebo groups.4
Limitations
This is a route cohort within the same protocol as the oral report, not evidence from an unrelated replication. Follow-up and surrogate endpoints limit conclusions about long-term outcomes.4
Reviewed study record
Renal-function pharmacokinetic study
Design
A single-exposure study compared pharmacokinetics across renal-function groups with four weeks of follow-up, registered as NCT06559527.5
Population
Forty-two adults participated: 14 with normal renal function and seven each with mild, moderate or severe impairment or end-stage renal disease.5
Outcomes reported
The authors reported broadly comparable exposure measurements across groups. Treatment-emergent adverse events occurred in 30 of 42 participants; none were serious or severe, and most were mild gastrointestinal events.5
Limitations
Small groups, one exposure and short follow-up do not establish long-term safety or therapeutic benefit in people with kidney disease. The report does not support individualized treatment recommendations.5
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)01176-6. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)01185-7. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)01247-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)01248-1. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.71096. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
NCT06064006 records 125 participants in a completed study of subcutaneous NNC0487-0111. NCT06049329 records a separate 36-participant oral study in Japanese men. These populations and routes should not be pooled as one trial. NCT06064006 ↗NCT06049329 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
The registered primary questions concerned adverse events
Both records list treatment-emergent adverse events as primary outcomes, with different observation windows across study parts. A weight change reported elsewhere is not automatically the primary endpoint of either registered study. NCT06064006 ↗NCT06049329 ↗
Enrollment was selective
The subcutaneous study enrolled adults aged 18–55 within a specified BMI range and excluded diabetic-range HbA1c. The oral study was restricted to Japanese men. These designs do not establish effects across all ages, diabetes populations or demographic groups. NCT06064006 ↗NCT06049329 ↗
Completion does not supply registry results
Both retrieved records are marked completed but contain no posted summary-results section. This is a registry-specific observation as of September 19, 2026, not a claim that trial publications or other reports do not exist. NCT06064006 ↗NCT06049329 ↗
What remains to be checked
Match oral and subcutaneous publications to exact protocols and reconcile their analysis populations.
Review later trials and result postings without treating these selected records as a complete development inventory.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary reports of the named peptide administered in people, including pharmacology and secondary human-sample analyses. Reviews, modeling and preclinical reports remain indexed but are outside this human-administration subset.
24 retrieved · 5 included · 18 excluded · 1 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"amycretin"[Title/Abstract] OR "zenagamtide"[Title/Abstract]
Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.
Showing 24 of 24 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42532080 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06542874.
PubMed 42532079 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06542874.
PubMed 42443140 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06559527.
PubMed 40550231 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06064006.
PubMed 40550229 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT05369390.
PubMed 40550232 — unresolved: No abstract in the retained record; the commentary-like title alone is insufficient for a definitive eligibility decision.
PubMed 42673585 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 42568490 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 42452898 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 42444567 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 42315994 — exclude: Modular chemical assembly and cell assays, not a human amycretin administration study.
PubMed 42208956 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 42175595 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 41948476 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 41850421 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 41747885 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 41344603 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 41255585 — exclude: Synthetic-data reconstruction and computational modeling of prior studies; no new participants receiving amycretin.
PubMed 41054801 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 40949933 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 40706446 — exclude: Mice, rats and cell-based experiments, outside the human-administration subset.
PubMed 40206909 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 40081498 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
PubMed 39204092 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
ClinicalTrials.gov search
ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.
27 retrieved · 27 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
amycretin OR zenagamtide OR "NNC0487-0111" OR "NNC0487-0113"
Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
Other registries and unregistered studies are outside this search.
Showing 25 of 27 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT07757087 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07757087.
ClinicalTrials.gov NCT06461039 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06461039.
ClinicalTrials.gov NCT07533175 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07533175.
ClinicalTrials.gov NCT07815067 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07815067.
ClinicalTrials.gov NCT06049329 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06049329.
ClinicalTrials.gov NCT07535307 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07535307.
ClinicalTrials.gov NCT07668414 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07668414.
ClinicalTrials.gov NCT07668401 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07668401.
ClinicalTrials.gov NCT07508020 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07508020.
ClinicalTrials.gov NCT07567001 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07567001.
ClinicalTrials.gov NCT06064006 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06064006.
ClinicalTrials.gov NCT07797335 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07797335.
ClinicalTrials.gov NCT06542874 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06542874.
ClinicalTrials.gov NCT07503210 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07503210.
ClinicalTrials.gov NCT07339423 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07339423.
ClinicalTrials.gov NCT05369390 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05369390.
ClinicalTrials.gov NCT06559527 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06559527.
ClinicalTrials.gov NCT07571109 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07571109.
ClinicalTrials.gov NCT07121153 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07121153.
ClinicalTrials.gov NCT07571005 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07571005.
ClinicalTrials.gov NCT07509307 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07509307.
ClinicalTrials.gov NCT07400107 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07400107.
ClinicalTrials.gov NCT06820476 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06820476.
ClinicalTrials.gov NCT06478563 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06478563.
ClinicalTrials.gov NCT07720271 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07720271.
FDA search
Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
products.active_ingredients.name:"AMYCRETIN" OR products.active_ingredients.name:"ZENAGAMTIDE" OR products.active_ingredients.name:"NNC0487-0111" OR products.active_ingredients.name:"NNC0487-0113"
This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Amycretin?
In clinical trials; not FDA-approved. Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.↗↗↗↗↗↗↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
6 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.
PhasesPhase 3 6
Status at observationNot yet recruiting 4Recruiting 2
PubMed bibliography
Publication composition
0 of 3 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Bibliography fields unavailable here for 3 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
9
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 9 dated records
We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT07668401 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07720271 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was amycretin.
Selected records span July 14, 2025 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT07931495 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.↗
PeptideScanner retained ClinicalTrials.gov record NCT07931547 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.↗
PeptideScanner retained ClinicalTrials.gov record NCT07861100 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was amycretin.↗
PeptideScanner retained ClinicalTrials.gov record NCT07720271 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was amycretin.↗
PeptideScanner retained ClinicalTrials.gov record NCT07797335 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-01, and PeptideScanner's reviewed identity mapping was amycretin.↗
PeptideScanner retained ClinicalTrials.gov record NCT07668401 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was amycretin.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗